VIENNA (MedPage Today) -- Treatment with gefitinib, a targeted EGFR inhibitor, failed to improve survival in advanced esophageal cancer but did slow disease progression, according to a study reported here. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment